Nektar Therapeutics (NKTR)
37.72
+0.83
(+2.25%)
USD |
NASDAQ |
Oct 15, 16:00
37.75
+0.03
(+0.08%)
After-Hours: 20:00
Nektar Therapeutics Cash from Operations (TTM) : -233.79M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -233.79M |
| March 31, 2026 | -203.76M |
| December 31, 2025 | -208.51M |
| September 30, 2025 | -189.74M |
| June 30, 2025 | -184.91M |
| March 31, 2025 | -176.87M |
| December 31, 2024 | -175.71M |
| September 30, 2024 | -176.57M |
| June 30, 2024 | -174.76M |
| March 31, 2024 | -188.58M |
| December 31, 2023 | -192.61M |
| September 30, 2023 | -203.26M |
| June 30, 2023 | -244.03M |
| March 31, 2023 | -267.50M |
| December 31, 2022 | -304.01M |
| September 30, 2022 | -397.84M |
| June 30, 2022 | -416.09M |
| March 31, 2022 | -424.00M |
| December 31, 2021 | -412.66M |
| September 30, 2021 | -359.76M |
| June 30, 2021 | -311.30M |
| March 31, 2021 | -312.30M |
| December 31, 2020 | -313.29M |
| September 30, 2020 | -339.88M |
| June 30, 2020 | -355.84M |
| Date | Value |
|---|---|
| March 31, 2020 | -325.86M |
| December 31, 2019 | -328.68M |
| September 30, 2019 | -321.01M |
| June 30, 2019 | -323.78M |
| March 31, 2019 | 689.78M |
| December 31, 2018 | 718.21M |
| September 30, 2018 | 755.36M |
| June 30, 2018 | 919.85M |
| March 31, 2018 | -98.31M |
| December 31, 2017 | -80.41M |
| September 30, 2017 | -52.42M |
| June 30, 2017 | -172.86M |
| March 31, 2017 | -127.94M |
| December 31, 2016 | -117.02M |
| September 30, 2016 | -139.72M |
| June 30, 2016 | -126.39M |
| March 31, 2016 | -160.04M |
| December 31, 2015 | -73.08M |
| September 30, 2015 | -22.60M |
| June 30, 2015 | -54.57M |
| March 31, 2015 | -16.40M |
| December 31, 2014 | -142.01M |
| September 30, 2014 | -63.75M |
| June 30, 2014 | -37.45M |
| March 31, 2014 | -62.71M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Eli Lilly & Co. | 28.08B |
| Inovio Pharmaceuticals, Inc. | -80.58M |
| Tonix Pharmaceuticals Holding Corp. | -155.18M |
| Capricor Therapeutics, Inc. | -104.00M |
| Kyntra Bio, Inc. | -38.05M |